


# UBS Floating Rate Income Bond Fund USD

## Performance Review

UBS (Lux) Bond SICAV - Floating Rate Income (USD) (EUR hedged) Q-dist



### Performance (basis EUR, net of fees)<sup>1</sup>



Past performance is not a reliable indicator of future results.

### Performance in % (net of fees)<sup>1</sup>

	· · · · · · · · · · · · · · · · · · ·		,					
in %	2020	2021	2022	2023	2024	Aug.	5 years Ø	) p.a. 5
					YTD <sup>2</sup>	2024		years
Fund (EUR)	-2.23	3.43	-1.48	11.94	5.46	0.38	19.43	3.61
The performance	e shown do	es not ta	ike accou	unt of an	y commis	sions, e	entry or ex	it

charges.

These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset Management. YTD: year-to-date (since beginning of the year)

Global fixed income markets had a positive month on the back of macro data and confirmation that the Fed will likely cut rates in September. After widening initially amid a global sell-off that was triggered by weakerthan-expected jobs data, spreads quickly recovered and traded tighter as subsequent data highlighted the resiliency of the US economy.

### Monthly performance

In August the fund performed positively with 0.4%. High carry and tightening spreads offset the impact of falling global government bond yields, driving the total return into positive territory.

### YTD performance

YTD as of the end of August, the fund has delivered a positive performance of 5.5%. High levels of income and tighter spreads across global developed high-yield markets have been the primary drivers of returns. Higher interest rates have also contributed given the floating-rate nature of the strategy.

### **Performance contributors**

Credit rated CCC outperformed other credit quality. US high yield outperformed EUR high yield this month. By industry, healthcare, technology and telecommunications were the top performers.

### **Performance detractors**

Credit rated BB underperformed. By industry, machinery, consumer products and banks & thrift underperformed on a relative basis.

For more information UBS Fund Infoline: 0800 899 899 Internet: www.ubs.com/funds Contact your client advisor Portfolio management representatives

Matthew lannucci **Branimir Petranovic Robert Martin** 

## UBS Floating Rate Income Bond Fund USD

### Credit quality (%)

		Fund	
BBB		6.2	
BB		28.3	
В			61.3
ССС		2.3	
Cash & Equivalents		2.4	
Not rated	-0.6		

## 5 largest positions (%)

	Fund
Nidda Healthcare Holding	2.5
Xerox Holdings Corp	2.3
Cirsa Finance International	2.1
Ford	1.9
APX Group Inc	1.7

### Investment instrument exposure (%)

		Fund
Floating Rate Note		64.6
Physical Floating Rate Notes		33.1
Cash & Equivalents		2.4
Credit Derivatives	-0.1	

## Sector exposure (%)

	Fund
Industrials	73.9
Financials	16.3
Utility	2.1
Securitized	1.2
Government-Entities	0.5
Interest Rate Derivatives Related -0.1	
Others	6.3

## Current investment strategy

We increased our exposure to US markets as opportunities arose, while maintaining high allocations to European markets as the floating rate market is heavily skewed towards Europe.

## Risks

The fund's net asset value depends on interest rate and credit spread movements and will be negatively affected should any issuer held in the portfolio default. Depending on the credit quality, default risk is higher with high yield bonds than with investment grade corporate and government bonds. The fund may use derivatives, which involve counterparty risk and higher loss risk versus security investments as the option, future and swap markets are volatile. The fund may invest in emerging markets, which are at an early stage of development and typically involve high price volatility, lower market transparency, regulatory hurdles, corporate governance, political and social challenges, etc. All investments are subject to market fluctuations. Every fund has specific risks, which may increase considerably in unusual market conditions. This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Information Document, Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 6 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on www.ubs.com/funds. Before investing in a product please read the latest prospectus and key information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the fund level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions' and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-glossary.